Navigation Links
Perrigo Confirms First to File Patent Challenge for Generic Version of Testosterone Gel 1.62%
Date:2/19/2013

ALLEGAN, Mich., Feb. 19, 2013 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO; TASE) announced that it has filed with the U.S. Food and Drug Administration (FDA) an Abbreviated New Drug Application for testosterone gel 1.62% and that it has notified AbbVie Inc., the owner of the Reference Listed Drug of its filing.

(Logo: http://photos.prnewswire.com/prnh/20120301/DE62255LOGO )

On February 15, 2013, the Unimed Pharmaceuticals subsidiary of AbbVie and Besins Healthcare filed suit against Perrigo in the United States District Court for the District of Delaware, alleging patent infringement. This action formally initiates the process under the Hatch-Waxman Act. Perrigo believes that it is a first filer for this opportunity, entitling it to 180 days of generic exclusivity.

Androgel® 1.62% (testosterone gel 1.62%) is indicated to treat males who have low or no testosterone. Annual sales were approximately $680 million annually, as measured by Wolters Kluwer Health.

Perrigo's Chairman and CEO Joseph C. Papa stated, "This filing is another example of our investment in new products and continued focus on bringing extended topicals to market. As always, Perrigo is committed to making quality healthcare more affordable for our customers and consumers."

Previously, on November 2, 2011, Perrigo announced that it filed with the FDA a New Drug Application for testosterone gel 1.0% and that it notified Abbott Products Inc., the owner of the Reference Listed Drug of its filing (http://perrigo.investorroom.com/2011-11-02-Perrigo-Confirms-Filing-for-Testosterone-Gel-1.0-and-Announcement-of-Patent-Infringement-Lawsuit-by-Abbott).          

From its beginnings as a packager of generic home remedies in 1887, Allegan, Michigan-based Perrigo Company has grown to become a leading global provider of quality, affordable healthcare products. Perrigo develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, pet health, dietary supplements and active pharmaceutical ingredients (API). The Company is the world's largest manufacturer of OTC pharmaceutical products for the store brand market. The Company's primary markets and locations of logistics operations have evolved over the years to include the United States, Israel, Mexico, the United Kingdom, India, China and Australia. Visit Perrigo on the Internet (http://www.perrigo.com).

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections.  While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 30, 2012, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Perrigo Company
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Perrigo Company To Present At The Leerink Swann Global Healthcare Conference
2. Perrigo Company Acquires U.K.-based Rosemont Pharmaceuticals Ltd. For Approximately £180 Million Or $283 Million
3. Perrigo Confirms FDA Approval For Testosterone Gel 1%
4. Perrigo Reports Record Second Quarter Revenue, Adjusted Earnings and Operating Cash Flow
5. Perrigo Company To Acquire OTC Companion Animal Health Company, Velcera, Inc., For $160 Million
6. Perrigo Commences Launch Of Clobetasol Emulsion Propionate Foam, 0.05%
7. Perrigo Company To Release Second Quarter Fiscal Year 2013 Results On February 1, 2013
8. Perrigo Company Announces The Appointment Of Industry Veteran To Executive Vice President And General Manager, Rx
9. Perrigo Announces FDA Final Approval Of Betamethasone Valerate Foam 0.12%
10. Perrigo Company To Present At The Credit Suisse Healthcare Conference
11. Perrigo Reports Record First Quarter Revenue And Adjusted Earnings And Raises Full Year Adjusted EPS Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... 2016 On Thursday, Feb. 11, 2016, surgeons ... David,s North Austin Medical Center successfully completed the first ... ® Surgical System with Trumpf Medical,s advanced operating ... Lakshman , M.D., colorectal surgeon at the Texas Institute ... Table Motion technology, which seamlessly combines the da Vinci ...
(Date:2/12/2016)... , Feb. 12, 2016  Aralez Pharmaceuticals Inc. (Nasdaq: ... announced the Company will ring the Nasdaq Closing Bell ... New York at 4:00 p.m. ET on ... Aralez. Adrian Adams , will perform ... 3:50 to 4:00 p.m. ET.  A live webcast will ...
(Date:2/12/2016)... , Feb. 12, 2016  Apellis Pharmaceuticals, ... a $47.1 million Series D preferred stock ... Management, Hillhouse Capital Group and venBio Global ... Investments, AJU IB Investment, and Epidarex Capital. The ... to further advance clinical trials in the ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... February 12, 2016 , ... Fixed Dose ... – 3:00 p.m. EST, http://www.fdanews.com/fixeddosecombination , Fixed dose ... products, garnering increased attention from all stakeholders in the development of new chemical ...
(Date:2/12/2016)... ... February 12, 2016 , ... The ThedaCare Center for Healthcare ... Hospital on April 5-7. The series is a multi-day, multi-workshop event designed to ... cover a broad range of topics, including coaching skills, the scientific method of ...
(Date:2/12/2016)... ... 12, 2016 , ... The Jones Agency, a family owned insurance company with ... a cooperative charity drive with the Tarrant Area Food Bank in the hopes of ... families in need, the Tarrant County Food Bank offers hope and security to the ...
(Date:2/12/2016)... ... 2016 , ... Miami Dental Specialists is excited to bring patients the choice ... in January, Miami Dental Specialists will offer the non-metal implants as a safe, holistic ... be chosen by the dental implant manufacturer, Straumann, to bring this cutting-edge technology to ...
(Date:2/12/2016)... ... February 12, 2016 , ... Atlantic Information Services, ... Plans and PBMs,” an upcoming Feb. 24 webinar that will discuss ways health ... therapeutic categories, such as the $1,000-per-pill hepatitis C treatment Sovaldi and high-cost PCSK9 ...
Breaking Medicine News(10 mins):